Table 3.

Summary of the disease state in the cervix and vagina of mice after 6 months with estrogen

Mouse genotypeSeverity of disease*
HCIN1CIN2CIN3MICLIC
CervixNTG511
K14E7WT112792
K14E7WTE6AP−/−2131
K14E6WTE7WT§386
K14E6WTE7WTE6AP−/−123
VaginaHVAIN1VAIN2VAIN3MICLIC
NTG511
K14E7WT24718
K14E7WTE6AP−/−241
K14E6WTE7WT§122111
K14E6WTE7WTE6AP−/−1221
  • *Cohorts of female mice of the indicated genotypes were treated with estrogen for 6 mo, and the reproductive tracts from every mouse were scored for the worst state (severity) of cervical (top half) or vaginal (bottom half of table) disease. The overall severity of disease between different genotypes was compared using a two-sided Wilcoxon rank sum test.

  • Regardless of E6AP status, the shift in the severity of disease in transgenic mice expressing HPV E7 in the presence or absence of E6 was all highly significant relative to NTG mice (P < 0.001).

  • Loss of E6AP did not result in a reduction in the severity of disease in K14E7WTE6AP−/− and was not significantly different than K14E7WT.

  • §The severity of disease is significantly increased in K14E6WTE7WT transgenic mice in the cervix (P = 0.001) and in the LRT (P = 0.07) relative to K14E7WT mice.

  • Loss of E6AP resulted in a reduction in the severity of disease in K14E6WTE7WTE6AP−/− transgenic mice both in the cervix (P = 0.006) and in the LRT (P = 0.01) relative to K14E6WTE7WT mice; the resulting severity of disease is similar to K14E7WTE6AP−/− mice (P > 0.05).